On December 25, Daiichi Sankyo announced that it has added new indications for injectable detrutuzumab in China. It has been approved for the treatment of adult breast cancer patients with unresectable or metastatic hormone receptor positive, low HER2 expression, or extremely low HER2 expression. It is the first HER2 targeted therapy for patients who have progressed through one or more endocrine treatments during the metastatic disease stage.

On December 25, Daiichi Sankyo announced that it has added new indications for injectable detrutuzumab in China. It has been approved for the treatment of adult breast cancer patients with unresectable or metastatic hormone receptor positive, low HER2 expression, or extremely low HER2 expression. It is the first HER2 targeted therapy for patients who have progressed through one or more endocrine treatments during the metastatic disease stage.